Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme

27Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Despite contemporary surgery, image-guided radiotherapy, and chemotherapy, glioblastoma multiforme (GBM) persists or relapses in nearly all patients, and tumors almost always recur locally. Management of recurrent GBM is variable, but approaches include best supportive care, reoperation, reirradiation, and/or systemic therapy. Promising novel therapies include antiangiogenic agents and stereotactic radiosurgery, which have cytotoxic effects on tumor microvasculature. Emerging data suggest the safety and efficacy of bevacizumab and radiosurgery either alone or in combination. This report presents the case of a man with locally recurrent GBM treated with stereotactic radiosurgery and concurrent bevacizumab, and reviews the preclinical and clinical data supporting this approach. © JNCCN - Journal of the National Comprehensive Cancer Network.

Cite

CITATION STYLE

APA

Cabrera, A. R., Cuneo, K. C., Vredenburgh, J. J., Sampson, J. H., & Kirkpatrick, J. P. (2012). Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. JNCCN Journal of the National Comprehensive Cancer Network, 10(6), 695–699. https://doi.org/10.6004/jnccn.2012.0072

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free